These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 17372025)
21. Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy. Linhart B; Focke-Tejkl M; Weber M; Narayanan M; Neubauer A; Mayrhofer H; Blatt K; Lupinek C; Valent P; Valenta R J Immunol; 2015 Apr; 194(8):4008-18. PubMed ID: 25786690 [TBL] [Abstract][Full Text] [Related]
22. Recombinant monoclonal human immunoglobulin E to investigate the allergenic activity of major grass pollen allergen Phl p 5. Madritsch C; Flicker S; Scheiblhofer S; Zafred D; Pavkov-Keller T; Thalhamer J; Keller W; Valenta R Clin Exp Allergy; 2011 Feb; 41(2):270-80. PubMed ID: 21143538 [TBL] [Abstract][Full Text] [Related]
23. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy increases CD4+CD25+ T cells in the nasal mucosa of subjects with allergic rhinitis. Asai K; Foley SC; Sumi Y; Yamauchi Y; Takeda N; Desrosiers M; Lavigne F; Hamid Q Allergol Int; 2008 Dec; 57(4):377-81. PubMed ID: 18797179 [TBL] [Abstract][Full Text] [Related]
24. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects. Winther L; Malling HJ; Mosbech H Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446 [TBL] [Abstract][Full Text] [Related]
25. The high molecular mass allergen fraction of timothy grass pollen (Phleum pratense) between 50-60 kDa is comprised of two major allergens: Phl p 4 and Phl p 13. Suck R; Hagen S; Cromwell O; Fiebig H Clin Exp Allergy; 2000 Oct; 30(10):1395-402. PubMed ID: 10998015 [TBL] [Abstract][Full Text] [Related]
26. Grass pollen immunotherapy induces highly cross-reactive IgG antibodies to group V allergen from different grass species. van Ree R; Brewczyński PZ; Tan KY; Mulder-Willems HJ; Widjaja P; Stapel SO; Aalberse RC; Kroon AM Allergy; 1995 Mar; 50(3):281-3. PubMed ID: 7677246 [TBL] [Abstract][Full Text] [Related]
27. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. Francis JN; James LK; Paraskevopoulos G; Wong C; Calderon MA; Durham SR; Till SJ J Allergy Clin Immunol; 2008 May; 121(5):1120-1125.e2. PubMed ID: 18374405 [TBL] [Abstract][Full Text] [Related]
28. Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen. Vrtala S; Fischer S; Grote M; Vangelista L; Pastore A; Sperr WR; Valent P; Reichelt R; Kraft D; Valenta R J Immunol; 1999 Nov; 163(10):5489-96. PubMed ID: 10553075 [TBL] [Abstract][Full Text] [Related]
29. Sublingual immunotherapy affects specific antibody and TGF-beta serum levels in patients with allergic rhinitis. Ciprandi G; De Amici M; Tosca MA; Pistorio A; Marseglia GL Int J Immunopathol Pharmacol; 2009; 22(4):1089-96. PubMed ID: 20074473 [TBL] [Abstract][Full Text] [Related]
30. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. Nouri-Aria KT; Pilette C; Jacobson MR; Watanabe H; Durham SR J Allergy Clin Immunol; 2005 Jul; 116(1):73-9. PubMed ID: 15990777 [TBL] [Abstract][Full Text] [Related]
31. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Shamji MH; Ljørring C; Francis JN; Calderon MA; Larché M; Kimber I; Frew AJ; Ipsen H; Lund K; Würtzen PA; Durham SR Allergy; 2012 Feb; 67(2):217-26. PubMed ID: 22077562 [TBL] [Abstract][Full Text] [Related]
32. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis. Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949 [TBL] [Abstract][Full Text] [Related]
33. Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. James LK; Bowen H; Calvert RA; Dodev TS; Shamji MH; Beavil AJ; McDonnell JM; Durham SR; Gould HJ J Allergy Clin Immunol; 2012 Sep; 130(3):663-670.e3. PubMed ID: 22583928 [TBL] [Abstract][Full Text] [Related]
34. Generation of a low immunoglobulin E-binding mutant of the timothy grass pollen major allergen Phl p 5a. Wald M; Kahlert H; Weber B; Jankovic M; Keller W; Cromwell O; Nandy A; Fiebig H Clin Exp Allergy; 2007 Mar; 37(3):441-50. PubMed ID: 17359394 [TBL] [Abstract][Full Text] [Related]
35. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570 [TBL] [Abstract][Full Text] [Related]